Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Long-Term Investments (2020 - 2025)

Universe Pharmaceuticals' Long-Term Investments history spans 6 years, with the latest figure at $702.3 million for Q3 2025.

  • On a quarterly basis, Long-Term Investments fell 1.42% to $702.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $702.3 million, a 1.42% decrease, with the full-year FY2025 number at $702.3 million, down 1.42% from a year prior.
  • Long-Term Investments hit $702.3 million in Q3 2025 for Universe Pharmaceuticals, down from $712.5 million in the prior quarter.
  • Over the last five years, Long-Term Investments for UPC hit a ceiling of $712.5 million in Q3 2024 and a floor of $586674.0 in Q1 2022.
  • Historically, Long-Term Investments has averaged $265.1 million across 5 years, with a median of $736489.5 in 2021.
  • Biggest five-year swings in Long-Term Investments: crashed 100.0% in 2021 and later soared 99822.61% in 2023.
  • Tracing UPC's Long-Term Investments over 5 years: stood at $744924.0 in 2021, then dropped by 5.64% to $702890.0 in 2022, then soared by 99822.61% to $702.3 million in 2023, then rose by 1.44% to $712.5 million in 2024, then fell by 1.42% to $702.3 million in 2025.
  • Business Quant data shows Long-Term Investments for UPC at $702.3 million in Q3 2025, $712.5 million in Q3 2024, and $692492.0 in Q1 2024.